Northstrive Biosciences Acquired by Modulant Biosciences | Healthcare M&A Deal

Modulant Biosciences has completed the acquisition of Northstrive Biosciences, a veterinary business in California, for $undisclosed. Northstrive Biosciences develops EL-22 and EL-32 myostatin-engineered probiotic technologies aimed at muscle preservation for non-human animal health, including feed additive applications. Modulant Biosciences acquisitions expand Modulant’s animal health and nutrition pipeline by licensing proprietary IP targeting myostatin and activin-A pathways for livestock productivity, feed efficiency, and companion animal muscle health and aging. The healthcare M&A deal is categorized as other acquisition and is a strategic acquisition by a strategic buyer, with an exclusive, royalty-bearing, sublicensable worldwide license excluding the Republic of Korea. Modulant is responsible for development, manufacturing, regulatory, and commercialization in the animal health field, while human pharmaceutical or clinical applications are excluded.